Varicella paediatric hospitalisations in Belgium : a 1-year national survey by Blumental, Sophie et al.
Varicella paediatric hospitalisations in Belgium:
a 1-year national survey
Sophie Blumental,1 Martine Sabbe,2 Philippe Lepage,1 the Belgian Group for Varicella
▸ Additional material is
published online only. To view
please visit the journal online
(http://dx.doi.org/10.1136/
archdischild-2015-308283).
1Paediatric Infectious Disease
Unit, Hôpital Universitaire des
Enfants Reine Fabiola
(HUDERF), Université Libre de
Bruxelles, Brussels, Belgium
2Unit of Epidemiology and
Infectious Diseases, Scientiﬁc
Institute of Public Health
(SIPH), Brussels, Belgium
Correspondence to
Professor Philippe Lepage,
Paediatric Infectious Disease
Unit, Hôpital Universitaire des
Enfants Reine Fabiola,
JJ Crocq avenue, 15,
Brussels 1020, Belgium;
philippe.lepage@huderf.be
Received 20 January 2015
Accepted 26 May 2015
To cite: Blumental S,
Sabbe M, Lepage P, et al.
Arch Dis Child Published
Online First: [please include
Day Month Year]
doi:10.1136/archdischild-
2015-308283
ABSTRACT
Background Varicella universal vaccination (UV) has
been implemented in many countries for several years.
Nevertheless, varicella UV remains debated in Europe and
few data are available on the real burden of infection. We
assessed the burden of varicella in Belgium through
analysis of hospitalised cases during a 1-year period.
Methods Data on children admitted to hospital with
varicella were collected through a national network from
November 2011 to October 2012. Inclusion criteria were
either acute varicella or related complications up to
3 weeks after the rash.
Results Participation of 101 hospitals was obtained,
covering 97.7% of the total paediatric beds in Belgium.
552 children were included with a median age of
2.1 years. Incidence of paediatric varicella hospitalisations
reached 29.5/105 person-years, with the highest impact
among those 0–4 years old (global incidence and odds of
hospitalisation: 79/105 person-years and 1.6/100
varicella cases, respectively). Only 14% (79/552) of the
cohort had an underlying chronic condition. 65% (357/
552) of children had ≥1 complication justifying their
admission, 49% were bacterial superinfections and 10%
neurological disorders. Only a quarter of children (141/
552) received acyclovir. Incidence of complicated
hospitalised cases was 19/105 person-years. Paediatric
intensive care unit admission and surgery were required in
4% and 3% of hospitalised cases, respectively. Mortality
among Belgian paediatric population was 0.5/106 and
fatality ratio 0.2% among our cohort.
Conclusions Varicella demonstrated a substantial
burden of disease in Belgian children, especially among
the youngest. Our thorough nationwide study, run in a
country without varicella UV, offers data to support
varicella UV in Belgium.
INTRODUCTION
Varicella (chickenpox), caused by the varicella-zoster
virus (VZV), usually presents as a vesicular eruption
associated with general symptoms like fever and
malaise. Endemic worldwide, this infection is self-
limiting in the vast majority of infected indivi-
duals.1 2 However, some complications are com-
monly described, mainly skin or disseminated
bacterial superinfections, central nervous system dis-
turbances, pneumonia and haematological disor-
ders.1 2 Although these complications are more
frequent and severe in high-risk subgroups (adults
and adolescents, pregnant women, immunocom-
promised patients), they can also affect otherwise
healthy children and subsequently increase the
burden of the disease, in addition to its high societal
and economic impact.
Safe and effective live-attenuated vaccines against
varicella were developed in the 1970s.3 Consequently,
varicella universal vaccination (UV) has been imple-
mented for >10 years in many countries such as the
USA, Canada, Australia and Germany, showing con-
clusive efﬁcacy results.4–9 According to recent
American and European studies, UV actually resulted
in a decrease of at least 88% in varicella incidence,
mortality, complicated cases and hospitalisations.4–11
Even though a slight shift of incidence peak was
noticed towards older children, the vaccination’s
impact was demonstrated to be signiﬁcant among all
age groups.6 10–12 Based on long-term epidemio-
logical surveillance, a global consensus was achieved
to recommend a 2-dose schedule, in order to avoid
breakthrough outbreaks and improve vaccine effect-
iveness and herd protection.13
Nevertheless, most European countries remain
hesitant to implement varicella UV (only imple-
mented in 5 out of 28 European Union coun-
tries).14 The main reasons are a poorly deﬁned
cost–beneﬁt balance in their own socioeconomic
setting and important concurrent priorities for
healthcare resource allocation. Additionally, some
concern arose about a temporary increase in herpes
What is already known on this topic?
▸ Varicella is usually a self-limiting disease but
complications are commonly described.
Universal vaccination (UV) against varicella has
shown good results in some countries but is
not largely implemented in Europe.
▸ Reliable data on the incidence and clinical
epidemiology of varicella among hospitalised
children are lacking in many countries, notably
Belgium.
What does this study add?
▸ This study shows a high burden of varicella
disease among otherwise healthy Belgian
children, as reﬂected by a signiﬁcant incidence
of paediatric varicella hospitalisation and
substantial rates of complications.
▸ The highest impact was observed among the
0–4 years old children.
▸ Our thorough nationwide study provides recent
data to support UV against varicella in
Belgium.
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zoster (HZ) after UV due to a lack of exogenous boosting.15 16
Although plausible and supported by mathematical models, this
hypothesis remains a source of debate.17 18
In Belgium, varicella incidence is estimated around 113 000
cases/year, leading to 28.8–35.7 general practitioners (GPs)
visits/104 people per year.19 However, routine varicella vaccin-
ation is not yet recommended in our country. The vaccination
coverage based on a subnational survey was estimated to be less
than 2.5% (2-dose schedule).20 Few data are available on the
real burden of varicella disease and on the potential beneﬁts
achievable from a national vaccination campaign in Belgium. In
this study, we prospectively assessed the burden of varicella
disease over the whole Belgian area through analysis of hospita-
lised cases during a 1-year period.
METHODS
Study design
This national survey was done in collaboration with the
Scientiﬁc Institute of Public Health (SIPH). The study used a
prospective design collecting all paediatric varicella-related hos-
pitalised cases over a 1-year period (1 November 2011 to 31
October 2012) in Belgium. All paediatric wards were identiﬁed
by cross between ministerial and national paediatric societies’
registers. All teams were invited to participate by personal
mailing and phone contacts, as well as through the recording
system of the SIPH.
Inclusion of eligible cases was ﬁrst prospectively carried out
by local teams concomitantly to their routine practice and then
retrospectively completed by a data-nurse reviewing admission
ﬁles and computerised ﬁle summaries. Clinical and epidemio-
logical data were recorded from medical ﬁles through a prede-
ﬁned electronic questionnaire. Data from non-participating
centres were recorded on log sheets to estimate the incidence of
disease as precisely as possible.
Case deﬁnitions
Strict deﬁnitions were used for varicella, varicella hospitalised
case, complicated case and rash intensity that are provided in
online supplementary appendix 1.
Study population
All children aged 0–15 years old meeting the above case deﬁnition
were eligible, regardless of their comorbidity or previous medical
history. Children with varicella but hospitalised for another reason
or admitted for <24 h were excluded. Nosocomial varicella infec-
tions were also excluded.
Ethics
The study protocol was approved by the ethics review commit-
tee of the coordinating centre (HUDERF) and submitted to the
ethics committee of the other participating hospitals. To ensure
conﬁdentiality, patients were identiﬁed using their initials, date
of birth and zip code only.
Statistical analysis
Epidemiological results are presented as rate of incidence of
varicella disease (total and complicated hospitalised cases) by
Belgian total and paediatric populations (population estimated
for those aged <16 years in 2011–2012). Differences between
groups were assessed by Fisher’s exact test or χ2 test for non-
continuous variables and Mann–Whitney U test for continuous
variables. A two-tailed p value of <0.05 was considered as stat-
istically signiﬁcant.
RESULTS
Epidemiological data
We collected data from 101 hospitals, covering 97.7% of the
total paediatric beds available in Belgium. Five hundred and
ﬁfty-two children hospitalised for varicella were recorded
during the study period. Based on the national demographic
data available on 1 January 2012,19 the incidence of
varicella-related paediatric hospitalisations and of complicated
hospitalised cases was 29.5/105 and 19/105 person-years,
respectively (table 1). Hospitalisation policy seemed homogen-
ous all over the country, since the distribution of collected cases
followed exactly the percentage of population allocated to each
of the three regions. The distribution of hospitalisation during
the study year showed the usual seasonal varicella peak occur-
ring around end of spring (May and June; data not shown).
The burden of disease was highest among preschool children
who represented the major part of the entire study cohort, as
well as of the complications (table 1). The proportion of com-
plicated cases among hospitalised patients was quite similar
between both 1–4 years and 5–14 years age groups (78% and
75%, respectively), but lower among children <1 year (51%).
The incidence of varicella-related ambulatory visits was
assessed at almost the same period through a sentinel network
of GPs.19 Among the population 0–4 years old, they reported
an average of GPs varicella outpatient visits of 495/104 people-
year. Taken together with our ﬁndings, we could estimate the
rate of hospitalisation per varicella case to be around 1.6% in
that preschool population (0–4 years old). Similar extrapolation
led to a rate of hospitalisation for complications among all vari-
cella cases of 1.0% in that age group.
Patients’ characteristics
Baseline characteristics of our cohort study are summarised in
table 2. The vast majority of patients were younger than the age
of 4 years old; 14% (79/552) had at least one underlying chronic
condition. Only four had received one dose of varicella vaccine
that was administered within the month before hospitalisation
except for one child vaccinated 6 months before admission.
Clinical features and complications
Fourteen per cent (79/552) of children presented with severe
vesicular rash on admission, whereas 17% (N=93) were
reported to have only a mild eruption as deﬁned above. The
median time between the ﬁrst lesions and hospitalisation was
3 days (range: 0–25 days). The main reasons for hospitalisation
were suspected bacterial infection (49%), poor general status
(20%), dehydration/anorexia (11%), the presence of neuro-
logical complications (10%), concomitant pneumonia (9%),
high-grade persisting fever (6%), stomatitis (5%), underlying
condition (5%), age below 3 months (3%) and social issues
Table 1 Incidence of varicella-related hospitalisations and
mortality among Belgian children
Age
group
(years)
N Belgian
children
2011–2012
Incidence
hospitalisation
for varicella*
Incidence
hospitalisation
for complicated
varicella*
Mortality
rate
0–14 1 873 326 29.5/105 19/105 0.5/106
0–4 647 171 79/105 51/105 1.5/106
5–14 1 226 155 3.3/105 2.45/105 0
*Person-years.
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(3%). Poor general status, high fever and feeding difﬁculties jus-
tiﬁed admission in 34% of the youngest children (<2 years).
The median duration of hospital stay was short (3 days, IQR 2–
5) but was up to 40 days in the most severe cases.
Sixty-ﬁve per cent (357/552) of children had one or more com-
plications detailed in ﬁgure 1. Globally, the presence of any bacter-
ial superinfection (not including pneumonia) represented
two-thirds of complicated cases (235 children, 43% of the entire
cohort). Bacterial skin and soft tissue infections were by far the
most common (59% of complicated cases, 204 children). Among
episodes with an available microbiology, meticillin-susceptible
Staphylococcus aureus and group A β-haemolytic Streptococcus
were the main causal pathogens. Only three children had
meticillin-resistant S. aureus infections. Neurological complica-
tions (N=56, 10%) consisted in febrile seizures (29/56), cerebelli-
tis with ataxia (13/56), encephalitis (6/56) and meningitis (2/56).
Forty-nine children (9% of the cohort) suffered from pneumonia;
out of them, 21 (43%) were recorded as having viral pneumonia,
whereas in the remaining 28 (57%), a bacterial aetiology was sus-
pected and treated accordingly. Rare complications included
haemorrhagic vesicular rash (two cases), staphylococcal scalded
skin syndrome (one case) and disseminated vasculitic purpura (one
case). Of interest, four babies had a neonatal varicella, all of which
were self-limiting. No Reye’s syndrome was reported.
Treatments
Only 26% (141/544, 7 missing data) of children received
acyclovir for a median duration of 5 days (IQR 3–5 days;
maximum 21 days). Out of them, 72% (101/141) received a
complete intravenous course. Valacyclovir was not prescribed.
In contrast, 58% (322/552) of the children received antibiotic
therapy that was administered intravenously for half of them.
Drugs most prescribed were amoxicillin–clavulanate (31%), peni-
cillin or oxacillin (22%) and clindamycin (7%). The median dur-
ation of therapy was 7 days (IQR 5–10 days, range 1–42 days).
Invasive surgery was part of patient’s management in 15 cases
(3%). Interventions consisted in abscess or pleural drainage,
joint aspiration and wound debridement.
Paediatric intensive care unit (PICU) admission was required
for 20 children (4%), with a median stay duration of 5 days
(range: 2–14 days). The main reasons for admission to PICU
were encephalitis/seizures (N=5), sepsis with haemodynamic
instability (N=4), poor general status with severe pain/dehydra-
tion (N=4), need for intensive observation due to underlying
condition (N=3), severe combined immunodeﬁciency (N=1)
and the presence of intestinal ileus (N=1). Four children (20%
of those admitted to PICU) needed mechanical ventilation and
one (5%) non-invasive ventilation support.
Outcome
One 17-month-old girl died from severe bacterial sepsis 6 days
after her varicella rash started. The diagnosis of toxic shock syn-
drome due to group A β-haemolytic Streptococcus was suspected
on clinical presentation though no microbiological conﬁrmation
could be obtained. The fatality rate among hospitalised cases
and complicated hospitalised cases was 0.2% and 0.3%, respect-
ively. According to analysis of death certiﬁcate records, the
varicella-related mortality rate inside the Belgian paediatric
population that was around 0.5/106 in our study was stable
during the last decade21 and in line with other European
reports (tables 1 and 3).
While the infection completely resolved in 99% (547/552) of
children, four of them (1%) had sequelae at discharge consisting
of reactive arthritis, ataxia, complex epilepsy or thrombophlebitis.
Moreover, 9% (51/552) of children were described as having sig-
niﬁcant skin scars.
DISCUSSION
In this national prospective study, we obtained data from 98%
of paediatric inpatient units in Belgium, allowing us to reliably
assess the burden of varicella disease in our country, both in
terms of incidence and severity, and to identify the paediatric
groups that will beneﬁt the most from vaccination. Because the
diagnosis of each varicella case was conﬁrmed by a paediatri-
cian, our data could be gathered in a more reliable manner com-
pared with others using only hospital computed databases.27
Limitations have, however, to be recognised. First, some chil-
dren might have been hospitalised for infectious complications
secondary to recent varicella that was not identiﬁed by the clini-
cians as the risk factor. The national VZV burden observed here
might therefore be underestimated. Second, our 1-year study
did not allow controlling for year-to-year variations in varicella
Table 2 Patients’ baseline characteristics
Total number of patients 552
Sex ratio (M/F) 1.3
Age (years)
Median 2.1
IQR 1–3.5
Range 0–15.7
Age groups distribution N (%)
0–4 years 512 (93)
<3 months 21 (4)
<1 year 137 (25)
5–14 years 40 (7)
Ethnicity N (%)
Caucasian 307 (56)
North Africa 50 (9)
Sub-Saharan Africa 17 (3)
Asia 17 (3)
South America 5 (1)
Oceania 1 (0.2)
Unknown 155 (28)
Comorbidity N (%)
Lung disease 22 (4)
Asthma 17 (3)
Neurological disorder 11 (2)
Renal disease/uropathy 10 (2)
Cancer 6 (1)
Cardiac disease 6 (1)
Gastrointestinal disease 5 (1)
Immunosuppressive therapy 3 (0.5)
Congenital immunodeficiency 3 (0.5)
Congenital malformation 3 (0.5)
Haematological disorder 2
Metabolic disorder 1
Varicella vaccine status N (%)
Unvaccinated 322 (58)
1 dose 4 (1)
Unknown 226 (41)
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incidence.28 Although the reported incidence might have suf-
fered from overestimation or underestimation, we demonstrated
a signiﬁcant burden of disease among the general childhood
population with highest impact in previously healthy young chil-
dren (0–4 years old). The varicella-related mortality was very
low, but the duration of hospitalisation was ≥5 days in 25% of
subjects.
As detailed in table 3, our data show a much higher incidence
of varicella hospitalisation than reported by other nationwide
studies from Europe.22–24 26 However, the design of these studies
(eg, inclusion criteria, deﬁnitions of complication) varies widely
from one country to another, making direct comparisons
extremely difﬁcult. Our results are nevertheless very similar to
those from neighbouring Northern France, where Dubos et al25
also included complicated and uncomplicated varicella cases. By
including all varicella hospitalised cases regardless of their sever-
ity, we attempted to obtain a real life overview of varicella-related
inpatients in our country. The reasons why more than one-third
of children classiﬁed as uncomplicated varicella were hospitalised
remain intriguing. The proportion of uncomplicated cases was
the highest among infants, which could illustrate paediatricians’
fear of varicella complications or parental difﬁculties in managing
the disease. A high frequency of uncomplicated inpatient vari-
cella cases (20–43%) has also been reported in other European
studies enrolling unselected hospitalised cases of varicella25 26 29
and deserves further investigation. Finally, it has recently been
estimated that the incidence of paediatric outpatient visits for
varicella in Belgium was 4950/105 person-years in children under
the age of 5 years old.19 Taking into account our incidence of
hospital admissions for varicella in this age group, we can esti-
mate the corresponding rates of hospitalisation and of compli-
cated hospitalisation among all varicella ambulatory cases to be
around 1.6% and 1.0%, respectively. This extrapolated result
reﬂects a high burden of varicella disease but has, however, to be
carefully considered, since the number of varicella outpatients
could be overestimated (recurrent consultations for the same
patient) or underestimated (additional visits to the paediatricians
or to the emergency room).
UV against varicella has been highly successful in many coun-
tries.6 4–12 In the USA, implementation of the one-dose varicella
immunisation programme in 1997 led to a 89.8% decrease in
the global incidence of varicella cases in 2005.6 Substantial
reduction in deaths, hospitalised cases, outpatient visits and
medical costs related to varicella were also demonstrated.10 11 In
Germany, similar results were published despite a lower cover-
age rate with a one-dose schedule.9 12 A 2-dose schedule
(including a second dose administered at variable ages) was
recently implemented by most countries with UV pro-
grammes.13 This signiﬁcantly improved the varicella vaccination
effectiveness by a further reduction in disease incidence and
breakthrough infections.30 Despite these successes, varicella UV
remains debated in most European countries and recommended
only for at-risk groups.27 Bonanni et al31 have, however, con-
cluded that vaccination targeting only adolescents and at-risk
groups was unable to interrupt virus transmission and was much
less efﬁcacious than UV. Additionally, our study as well as
others22–24 28 32–34 clearly demonstrate that most hospitalised
children with varicella were previously healthy; this constant
ﬁnding is a strong argument in favour of varicella UV. Our
recent comprehensive national survey now supports the imple-
mentation of varicella UV in Belgium and at least fuels the
debate in other European countries without UV.
Varicella vaccination has been shown to reduce the risk of HZ
in vaccinated children, though very long-term surveillance
remains needed.35 Debate continues about whether childhood
varicella UV might have a negative impact on the incidence of
HZ in adults with a history of varicella.15 27 36 It has been pos-
tulated that re-exposure to circulating VZV might decrease the
propensity of virus reactivation.15 If true, a consequence of this
‘exogenous boosting’ hypothesis could be a temporary increase
of HZ cases following the reduced circulation of VZV under the
inﬂuence of varicella vaccination. Whereas this could constitute
a serious counterargument against UV, epidemiological surveys
have not yet conﬁrmed this hypothesis.37 Long-term follow-up
in countries with UV demonstrated a slight increase in HZ inci-
dence that, however, started before implementation of
Figure 1 Distribution of
varicella-related complications. N=357
patients; 4S=staphylococcal scalded
skin syndrome.
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Table 3 Comparison of varicella burden in Europe
Country Year
Incidence
(/105 person-years)
Hospitalisation
rate
(/104 varicella
cases)
Cases
(n)
Median
age
(years)
Length of
hospital stay
(median in
days) Complications
Deaths
(n)
Fatality rate
(/hospitalised
cases) Sequelae
Mortality rate
(/105 person-years)
Cameron et al22 UK and
Ireland
2002–2003 0.82 na 188 3 7 Bacterial superinfections
46%
5 2.6 37%
(ataxia)
0.04
(severe hospitalised
cases)
CNS involvement 27%
Ziebold et al23 Germany 1997 0.85 5 119 na na Bacterial superinfections
61%
3 na 6.7% na
(severe hospitalised
cases)
CNS involvement 35%
Bonhoeffer
et al24
Switzerland 2000–2003 5.9 13 420 3.5 5 Bacterial superinfections
36%
3 0.5 4% na
(all hospitalised cases) CNS involvement 25%
Dubos et al25 North of
France
2003 25 na 162 1.75 4 Bacterial superinfections
29%
3 1.8 na 0.5
(all hospitalised cases) CNS involvement 26%
Liese et al26 Germany 2003–2004 14.1 na 918 3.3 5 Bacterial superinfections
23%
10 1 8.7% na
(all hospitalised cases) CNS involvement 25%
National
Belgian survey
Belgium 2011–2012 29.5 na 552 2.1 3 Bacterial superinfections
43%
1 0.20 1% 0.5
(all hospitalised cases) CNS involvement 10%
CNS, central nervous system.
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vaccination and was similar between regions, irrespective of
their vaccine coverage.38 Moreover, a recent study demonstrated
a comparable HZ incidence between speciﬁc adult communities
not exposed to VZV and the general population.18 So far, the
existence of exogenous boosting has been reported in some but
not all studies16 and its importance, as well as the immune path-
ways involved, still needs to be determined. Further long-term
studies assessing varicella and HZ burden are crucially needed
in countries with UV to better elucidate this issue. Furthermore,
vaccination against HZ for elderly people recently became avail-
able and started to be implemented in some countries.39
CONCLUSION
Varicella demonstrated a substantial burden of disease, especially
among the youngest and previously healthy children. Our thor-
ough nationwide study offers recent data to fuel the debate and
supports varicella UV in European countries. However, some
hypotheses still deserve further evaluation and postvaccination
long-term surveys are needed to assess the effectiveness and
costs–beneﬁts of this new potential vaccination policy.
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